According to a new study, triggering TREM2 could help slow the progression of some neurodegenerative diseases.
Testing for specific inflammatory proteins in cerebrospinal fluid can help doctors to diagnose the early onset of Alzheimer's disease and track the progression of the disease in patients.
Changes in gene expression help researchers identify ALS associated pathways and establish the key drivers of motor neuron degeneration in the disease.
The P522R gene variant increases expression levels of several microglia genes which are reduced in people with Alzheimer's disease.
Carries of the TREM2 genetic mutation associated with Alzheimer's disease could develop the disease up to three years earlier than expected, a new study finds.
Stimulating microglial cells could delay the onset of some neurodegenerative diseases, researchers report.
Study in mice and humans reveals reinforcing the activity of microglia could slow, or potentially halt, the proliferation of Tau tangles in Alzheimer's disease.
Stimulating activation of microglia may help eliminate Alzheimer's associated plaques, thus helping to prevent the progression of the neurodegenerative disease.
DHA treatment reduced the size of the damaged brain area and initiated a repair mechanism in animal models of stroke. DHA affected the levels of MANF and TREM2, two proteins critical for communication between brain cells.
Researchers have discovered an early immune response in people with a genetic predisposition to Alzheimer's disease.
Rapamycin, a drug approved for the treatment of cancer and transplant patients increases amyloid-beta protein plaques in the brains of mice.
Findings point to microglial TREM2 as a potential target for the treatment of ALS.
